Group 1 - 908 Devices Inc. reported a quarterly loss of $0.22 per share, better than the Zacks Consensus Estimate of a loss of $0.27, and an improvement from a loss of $0.33 per share a year ago, resulting in an earnings surprise of 18.52% [1] - The company posted revenues of $11.78 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.99%, but showing growth from $9.99 million in the same quarter last year [2] - 908 Devices shares have increased approximately 160.5% since the beginning of the year, contrasting with a decline of 0.6% in the S&P 500 [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $12.3 million, and for the current fiscal year, it is -$0.63 on revenues of $55.48 million [7] - The Medical - Instruments industry, to which 908 Devices belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8]

Revenue Performance - Revenue from continuing operations for the three months ended March 31, 2025, was $11.8 million, up from $7.4 million in the same period of 2024, representing a 59.5% increase[140] - Total revenue for the three months ended March 31, 2025, was $11.777 million, a 58.7% increase from $7.422 million in the same period of 2024[190] - Product revenue increased by $3.297 million, or 63%, to $8.529 million for the three months ended March 31, 2025, compared to $5.232 million in 2024[191] - Service and contract revenue rose by $1.058 million, or 48%, to $3.248 million for the three months ended March 31, 2025, compared to $2.190 million in 2024[195] Profitability and Losses - The company incurred net losses of $9.8 million for the three months ended March 31, 2025, compared to $5.9 million for the same period in 2024, indicating a 66.1% increase in losses[140] - Loss from operations for the three months ended March 31, 2025, was $(11.026) million, compared to $(7.611) million in the same period of 2024, representing a $3.415 million increase in losses[190] - Gross profit for the three months ended March 31, 2025, was $5.541 million, up 42.5% from $3.887 million in 2024[190] - Gross profit margin for product revenue decreased to 45% in Q1 2025 from 54% in Q1 2024, reflecting a 9 percentage point decline[191] Operating Expenses - Total operating expenses increased by $5.069 million, or 44.2%, to $16.567 million for the three months ended March 31, 2025, compared to $11.498 million in 2024[190] - Research and development expenses increased by $0.537 million, or 16.3%, to $3.829 million for the three months ended March 31, 2025, compared to $3.292 million in 2024[190] - Selling, general and administrative expenses increased to $10.2 million for the three months ended March 31, 2025, up by $2.0 million, or 25%, and accounted for 87% of total revenue[199] Cash Flow and Financial Position - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $124.3 million, sufficient to fund operations for at least the next twelve months[204] - Net cash used in operating activities was $15.0 million for the three months ended March 31, 2025, primarily due to noncash charges of $50.5 million and changes in operating assets and liabilities[212] - Net cash provided by investing activities was $50.3 million for the three months ended March 31, 2025, mainly from $69.9 million in proceeds from the sale of the Desktop Portfolio[214] - Cash used in financing activities was $0.2 million for the three months ended March 31, 2025, primarily for withholding taxes on vested equity awards[216] Strategic Outlook - The company expects to continue incurring net losses as it focuses on growing sales and scaling manufacturing operations[140] - The company plans to enhance its device technology and expand sales efforts to drive future growth[152] - The company plans to expand global sales efforts, particularly through distribution channels, as it assesses international market needs[190] - The company may seek additional funding through various means, including private or public equity financings and strategic alliances, but there is no assurance of obtaining funds on acceptable terms[209] Market and Economic Factors - The company is closely monitoring macroeconomic factors, including inflation and interest rates, which may impact its business and customer spending[143] Product and Placement Metrics - Recurring revenue accounted for 37% of total revenue for the three months ended March 31, 2025, slightly down from 38% in the same period of 2024[156] - Device sales represented 63% of total revenue for the three months ended March 31, 2025, compared to 62% for the same period in 2024[165] - The number of handheld product placements increased to 157 units for the three months ended March 31, 2025, up from 53 units in the same period of 2024, reflecting a 196.2% increase[163] - Cumulative product placements of handheld devices reached 3,172 units as of March 31, 2025, compared to 2,475 units as of March 31, 2024, marking a 28.2% increase[164] Contingent Consideration and Interest Income - The fair value of contingent consideration increased by $2.5 million due to the rise in the company's publicly quoted share price during the three months ended March 31, 2025[200] - Interest income decreased by $0.8 million to $0.9 million for the three months ended March 31, 2025, primarily due to a lower cash and marketable securities balance[201]

MAY 2025 Forward looking statements / Non-GAAP financial measures Analysis at the speed of life This presentation and the accompanying oral presentation (this "presentation") contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements may relate to, but are not limited to, expectations of future results of operations or financial performance of 908 Devices Inc. ( ...

Revenue Performance - Revenue from continuing operations for Q1 2025 was $11.8 million, a 59% increase year-over-year, primarily driven by an 86% increase in handheld product and service revenue[5] - Recurring revenue reached $4.4 million, up 54% year-over-year, representing 37% of total revenues for the quarter[8] - The company expects full-year 2025 revenues from continuing operations to be between $53 million and $55 million, indicating an 11% to 15% growth compared to 2024[12] Profitability Metrics - Adjusted gross profit for Q1 2025 was $6.4 million, with an adjusted gross margin of 54%, an increase of approximately 75 basis points compared to the prior year[6] - Gross profit (GAAP) for Q1 2025 was $5,541 million, up from $3,887 million in Q1 2024, representing a 42.5% increase[24] - Adjusted gross profit (Non-GAAP) for Q1 2025 was $6,409 million, compared to $3,983 million in Q1 2024, indicating a 60.8% growth[24] - Gross margin percentage (GAAP) decreased to 47% in Q1 2025 from 52% in Q1 2024[24] - Adjusted gross margin percentage (Non-GAAP) remained stable at 54% for both Q1 2025 and Q1 2024[24] - Adjusted EBITDA (Non-GAAP) improved to $(4,569) million in Q1 2025, compared to $(5,339) million in Q1 2024, showing a reduction in losses[24] Operating Expenses - Operating expenses increased to $16.6 million in Q1 2025 from $11.5 million in the prior year, influenced by a $2.5 million non-cash charge related to contingent consideration[7] - Stock-based compensation increased to $2,221 million in Q1 2025 from $1,839 million in Q1 2024[24] - Acquisition and integration costs rose to $640 million in Q1 2025, up from $274 million in Q1 2024[24] - Intangible amortization for Q1 2025 was $713 million, while there was none reported in Q1 2024[24] Net Loss - Net loss from continuing operations was $9.8 million for Q1 2025, compared to a net loss of $5.9 million in the same period last year[9] - Net loss from continuing operations (GAAP) increased to $(9,838) million in Q1 2025 from $(5,895) million in Q1 2024[24] Device and Market Metrics - The installed base of devices grew 28% year-over-year to 3,172 devices, with 157 devices placed during Q1 2025[5] - A $2.0 million order for MX908 mass spectrometry devices was received from the Texas Department of Public Safety for drug detection[8] Cash Position - Cash, cash equivalents, and marketable securities totaled $124.3 million as of March 31, 2025, with no debt outstanding[11] Corporate Actions - The company announced the divestiture of its bioprocessing product portfolio to Repligen Corporation on March 4, 2025[8] Fair Value Adjustments - Change in fair value of contingent consideration was $2,499 million in Q1 2025, with no comparable figure in Q1 2024[24]

The market expects 908 Devices Inc. (MASS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 13, 2025, might help the stock move higher if these key numbers ar ...

Core Viewpoint - Masivo Silver Corp. has completed the design of a strategic drill target program at the Cerro Colorado property in Sonora, Mexico, aiming to explore the potential for significant mineralization [1][2]. Drill Program Overview - The drill program consists of eight holes totaling 1,300 meters, designed by Senior Mexican Geologist Jorge Rafael Gallardo with input from P.Geo Brian Brewer and P.Geo Mark Bailey [1]. - The program is expected to enhance the understanding of the property's potential and unlock significant value [2]. Specific Drill Hole Objectives - **Hole A**: Targets a depth of 130 meters to hit a zone of polymetallic sulfides, with potential for high values of silver, gold, copper, lead, and zinc [2]. - **Hole B**: Planned approximately 500 meters northeast of Hole A, targeting a depth of 150 meters to test a high chargeability anomaly and follow up on historic high-grade values, including assays of 1,840 g/t silver, 4.82 g/t gold, 3.06% copper, 4.55% lead, and 2.92% zinc [3]. - **Holes C, D & E**: Positioned between Holes A and B, with Hole C and E targeting 150 meters and Hole D extending to 200 meters to test the same mineralized structure [4]. - **Holes F & G**: Planned to reach depths of 150 to 300 meters northeast of Hole B, aimed at assessing the continuity of the mineralized structure along a southwest-to-northeast trend [5]. - **Hole H**: Oriented to target a southeast-to-northwest structural system, which is perpendicular to the main trend, with a planned depth of 120 meters [6][7]. Geological Insights - The property features two distinct structural systems: one controlling Ag-Au-Cu-Pb-Zn mineralization and the other hosting Au-Cu-Ag, which may create highly fractured and porous zones conducive to mineralization [9].

Core Viewpoint - The article discusses the significant decline in stock prices of small-cap biopharma companies over the past couple of years, highlighting the case of 908 Devices (NASDAQ: MASS) as a notable example that was once favored by high-profile ETFs [1]. Group 1: Company Analysis - 908 Devices (NASDAQ: MASS) is identified as a small-cap biopharma company that has experienced a substantial drop in its stock price [1]. - The company was previously a favorite among high-profile ETFs, indicating its prior popularity and potential investor interest [1]. Group 2: Market Context - The article reflects on the broader trend affecting small-cap biopharma companies, suggesting a challenging market environment that has led to stock price declines [1].

Financial Performance - The company generated revenue of $35.2 million for the nine months ended September 30, 2022, compared to $26.4 million for the same period in 2021, representing a year-over-year increase of 33.3%[123] - The company incurred net losses of $23.8 million for the nine months ended September 30, 2022, compared to net losses of $18.7 million for the same period in 2021, indicating an increase in losses of 27.3%[123] - Total revenue for the nine months ended September 30, 2022, was $35,209 thousand, an increase of $8,844 thousand, or 33%, compared to $26,365 thousand in 2021[176] - The net loss for the three months ended September 30, 2022, was $6,259,000, compared to a net loss of $5,185,000 in the same period of 2021, reflecting a deterioration of $1,074,000[163] - Net loss for the nine months ended September 30, 2022, was $23,772 thousand, an increase of $5,068 thousand compared to a net loss of $18,704 thousand in 2021[176] Revenue Composition - Consumables and service revenue accounted for 29% of total product and service revenue for the nine months ended September 30, 2022, up from 21% for the same period in 2021[138] - Device sales revenue accounted for 71% of total product and service revenue for the nine months ended September 30, 2022, down from 79% in the same period of 2021[146] - Total product and service revenue rose by $3.2 million, or 26%, to $15,437 thousand for the three months ended September 30, 2022, compared to $12,285 thousand in 2021[165] Expenses - Research and development expenses for the three months ended September 30, 2022, increased to $4,666,000, up 41.3% from $3,302,000 in the same period of 2021[163] - Selling, general and administrative expenses rose to $11,826,000 for the three months ended September 30, 2022, a 34.6% increase from $8,786,000 in the same period of 2021[163] - Research and development expenses increased to $12.9 million for the nine months ended September 30, 2022, up 38% from $9.3 million in the same period of 2021[185] - Selling, general and administrative expenses rose to $32.3 million for the nine months ended September 30, 2022, reflecting a 38% increase from $23.3 million in 2021[187] Cash Flow and Financing - Cash used in operating activities was $15.8 million for the nine months ended September 30, 2022, compared to $19.9 million in the same period of 2021[200] - Net cash used in investing activities was $15.2 million for the nine months ended September 30, 2022, primarily due to the acquisition of Trace for $13.8 million[202] - Cash provided by financing activities was $0.8 million for the nine months ended September 30, 2022, mainly from common stock option exercises[203] - As of September 30, 2022, the company had cash and cash equivalents of $193.7 million, expected to fund operations for at least the next twelve months[190] Acquisitions and Investments - The company completed the acquisition of Trace for a total purchase price of $17.3 million, which includes an initial cash payment of $14.4 million and contingent cash consideration of up to $2.0 million[122] - The company plans to expand its commercial operations and may seek additional funding through various financing methods[197] Market and Economic Conditions - The company is closely monitoring economic uncertainty and rising inflation, which may impact customer orders and overall sales[127] - The company aims to mitigate downward pressure on average selling prices by increasing the value proposition of its devices and consumables[142] Product and Service Metrics - Total product placements for the three months ended September 30, 2022, were 175 units, a decrease of 4.9% from 184 units in the same period of 2021[144] - For the nine months ended September 30, 2022, total product placements increased to 382 units, up 8.2% from 353 units in the same period of 2021[144] - Cumulative product placements as of September 30, 2022, reached 2,317 units, a 35.1% increase from 1,714 units as of September 30, 2021[145] Accounting Policies and Estimates - There were no significant changes to critical accounting policies for the nine months ended September 30, 2022, except as discussed[214] - Recently issued accounting pronouncements that may impact financial position and results of operations are disclosed in the Quarterly Report[215] - The company qualifies as a smaller reporting company and is not required to provide certain market risk disclosures[216]

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Condensed Consolidated Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed consolidated financial statements for 908 Devices Inc., detailing financial position, performance, cash flows, and significant accounting policies [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2022, total assets decreased to **$247.0 million** from **$260.9 million** at year-end 2021, primarily due to reduced cash and cash equivalents Condensed Consolidated Balance Sheet Data (in thousands) | Account | June 30, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $212,994 | $224,073 | | Inventory | $11,178 | $7,918 | | Total current assets | $238,678 | $252,893 | | Total assets | $246,995 | $260,906 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $15,434 | $14,836 | | Long-term debt | $15,000 | $15,000 | | Total liabilities | $45,880 | $46,302 | | Accumulated deficit | $(118,151) | $(100,637) | | Total stockholders' equity | $201,115 | $214,604 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For the six months ended June 30, 2022, total revenue increased to **$19.4 million**, but net loss widened to **$17.5 million** due to higher operating expenses Statement of Operations Highlights (in thousands, except per share data) | Metric | Q2 2022 | Q2 2021 | Six Months 2022 | Six Months 2021 | | :--- | :--- | :--- | :--- | :--- | | Total revenue | $11,106 | $8,277 | $19,412 | $13,820 | | Gross profit | $6,634 | $4,379 | $10,763 | $7,287 | | Loss from operations | $(8,369) | $(7,455) | $(17,890) | $(13,265) | | Net loss | $(8,099) | $(7,424) | $(17,514) | $(13,519) | | Net loss per share (basic and diluted) | $(0.26) | $(0.27) | $(0.56) | $(0.49) | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) Total stockholders' equity decreased to **$201.1 million** as of June 30, 2022, primarily due to a **$17.5 million** net loss Changes in Stockholders' Equity (Six Months Ended June 30, 2022, in thousands) | Description | Amount | | :--- | :--- | | Balance at December 31, 2021 | $214,604 | | Net loss | $(17,514) | | Stock-based compensation expense | $3,183 | | Issuance of common stock (options/ESPP) | $1,382 | | Balance at June 30, 2022 | $201,115 | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities improved to **$10.9 million** for the six months ended June 30, 2022, with overall cash and equivalents decreasing by **$11.0 million** Cash Flow Summary (Six Months Ended June 30, in thousands) | Cash Flow Activity | 2022 | 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(10,876) | $(16,938) | | Net cash used in investing activities | $(689) | $(625) | | Net cash provided by (used in) financing activities | $597 | $(290) | | **Net decrease in cash** | **$(10,968)** | **$(17,853)** | | Cash at end of period | $213,165 | $141,374 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) These notes detail the company's business, accounting policies, customer concentration, disaggregated revenue, and the subsequent acquisition of TRACE Analytics GmbH - One customer accounted for **19% of total revenue** and **13% of gross accounts receivable** for the six months ended June 30, 2022[35](index=35&type=chunk) Disaggregated Revenue (Six Months Ended June 30, in thousands) | Revenue Stream | 2022 | 2021 | | :--- | :--- | :--- | | **By Type** | | | | Device sales revenue | $13,287 | $10,092 | | Consumables and service revenue | $5,350 | $3,180 | | License and contract revenue | $775 | $548 | | **Total Revenue** | **$19,412** | **$13,820** | | **By Geography** | | | | Americas | $15,538 | $10,489 | | Europe, Middle East and Africa | $2,601 | $2,171 | | Asia Pacific | $1,273 | $1,160 | - The company acquired TRACE Analytics GmbH on August 3, 2022, for an initial **$15.3 million** cash payment and up to **$2.0 million** in contingent consideration[84](index=84&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial performance, highlighting **40% revenue growth** in H1 2022, widening net losses due to strategic investments, and a sufficient liquidity position [Overview](index=26&type=section&id=Overview) The company develops and sells mass spectrometry devices, reporting **$19.4 million** in revenue and a **$17.5 million** net loss for H1 2022, with continued losses expected due to growth investments - The company manufactures purpose-built handheld (MX908) and desktop (Rebel, ZipChip) mass spectrometry devices for point-of-need analysis[89](index=89&type=chunk)[91](index=91&type=chunk) - For the six months ended June 30, 2022, the company generated **$19.4 million** in revenue and incurred a net loss of **$17.5 million**, with an accumulated deficit of **$118.2 million**[93](index=93&type=chunk) [Factors Affecting Our Performance](index=28&type=section&id=Factors%20Affecting%20Our%20Performance) Performance is driven by device sales, recurring revenue, and revenue mix, with recurring revenue representing **29%** of product and service revenue in H1 2022 - Device sales are a primary performance driver, with varying sales cycles depending on customer type, such as long cycles for government and variable cycles for pharma/biotech[100](index=100&type=chunk)[102](index=102&type=chunk)[103](index=103&type=chunk) - Recurring revenue from consumables and services, a key focus, represented **29%** of product and service revenue for the six months ended June 30, 2022, up from **24%** in the prior year[104](index=104&type=chunk) [Key Business Metrics](index=31&type=section&id=Key%20Business%20Metrics) Product placements, a key business metric, totaled **207 units** for the six months ended June 30, 2022, contributing to **2,142 cumulative placements** Product Placements (Units) | Device | Q2 2022 | Q2 2021 | Six Months 2022 | Six Months 2021 | | :--- | :--- | :--- | :--- | :--- | | MX908 | 102 | 84 | 165 | 137 | | Rebel | 14 | 12 | 29 | 21 | | ZipChip Interface | 8 | 7 | 13 | 11 | | **Total** | **124** | **103** | **207** | **169** | Cumulative Product Placements (Units) | Device | June 30, 2022 | June 30, 2021 | | :--- | :--- | :--- | | MX908 | 1,815 | 1,295 | | Rebel | 129 | 67 | | ZipChip Interface | 198 | 168 | | **Total** | **2,142** | **1,530** | [Results of Operations](index=35&type=section&id=Results%20of%20Operations) This section details financial results, showing **34% revenue growth** in Q2 2022 and **40%** for H1 2022, alongside increased operating expenses leading to wider losses Q2 2022 vs Q2 2021 Comparison (in thousands) | Metric | Q2 2022 | Q2 2021 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $11,106 | $8,277 | $2,829 | 34% | | Gross Profit | $6,634 | $4,379 | $2,255 | 51.5% | | Product & Service Gross Margin | 59% | 51% | 8 p.p. | - | | R&D Expenses | $4,293 | $3,055 | $1,238 | 41% | | SG&A Expenses | $10,710 | $8,779 | $1,931 | 22% | | Loss from Operations | $(8,369) | $(7,455) | $(914) | 12% | Six Months 2022 vs 2021 Comparison (in thousands) | Metric | H1 2022 | H1 2021 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $19,412 | $13,820 | $5,592 | 40% | | Gross Profit | $10,763 | $7,287 | $3,476 | 47.7% | | Product & Service Gross Margin | 55% | 52% | 3 p.p. | - | | R&D Expenses | $8,198 | $6,020 | $2,178 | 36% | | SG&A Expenses | $20,455 | $14,532 | $5,923 | 41% | | Loss from Operations | $(17,890) | $(13,265) | $(4,625) | 35% | [Liquidity and Capital Resources](index=42&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2022, the company held **$213.0 million** in cash, deemed sufficient for the next twelve months, with **$10.9 million** net cash used in operations for H1 2022 - The company held **$213.0 million** in cash and cash equivalents as of June 30, 2022[153](index=153&type=chunk) - Net cash used in operating activities for the six months ended June 30, 2022, was **$10.9 million**, an improvement from **$16.9 million** in the prior year[159](index=159&type=chunk)[160](index=160&type=chunk) - The company maintains a **$25.0 million** revolving line of credit, maturing in March 2024, subject to covenants including a **$10.0 million** minimum cash level[156](index=156&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=47&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, the company is not required to provide quantitative and qualitative disclosures about market risk - As a smaller reporting company, the company is not required to provide quantitative and qualitative disclosures about market risk[169](index=169&type=chunk) [Item 4. Controls and Procedures](index=47&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2022, with no material changes in internal control over financial reporting - Management concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of the report period end[170](index=170&type=chunk) - No material changes occurred in internal control over financial reporting during the most recently completed fiscal quarter[171](index=171&type=chunk) [PART II. OTHER INFORMATION](index=48&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=48&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings - The Company is not currently party to any material legal proceedings[174](index=174&type=chunk) [Item 1A. Risk Factors](index=48&type=section&id=Item%201A.%20Risk%20Factors) No material changes have occurred to the risk factors previously disclosed in the company's 2021 Annual Report on Form 10-K - There are no material changes to the risk factors discussed in the company's 2021 Annual Report on Form 10-K[175](index=175&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=48&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities and no material change in the planned use of IPO proceeds - There has been no material change in the planned use of IPO proceeds from that described in the final prospectus filed on December 18, 2020[179](index=179&type=chunk) [Item 3. Defaults Upon Senior Securities](index=48&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - No defaults upon senior securities were reported[181](index=181&type=chunk) [Item 4. Mine Safety Disclosures](index=48&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - This item is not applicable[182](index=182&type=chunk) [Item 5. Other Information](index=49&type=section&id=Item%205.%20Other%20Information) The company reports no other information for this item - No other information is reported for this item[183](index=183&type=chunk) [Item 6. Exhibits](index=50&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Quarterly Report on Form 10-Q, including CEO and CFO certifications and XBRL data - Exhibits filed include CEO and CFO certifications pursuant to Sarbanes-Oxley Act of 2002 and Inline XBRL documents[186](index=186&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39815 908 DEVICES INC. Registrant's telephone number, including area code: (857) 254-1500 Securities regist ...